Public health impact and cost-effectiveness of switching from bivalent to nonavalent vaccine for human papillomavirus in Norway: incorporating the full health impact of all HPV-related diseases

Ibrahim Diakitea Health Economic and Decision Sciences, Merck & Co., Inc., Rahway, NJ, USACorrespondence[email protected]

Sylvi Nguyenb MSD, Oslo, Norway

Ugne Sabalec Center for Observational and Real-World Evidence, MSD, Stockholm, Sweden

Andrew Pavelyeva Health Economic and Decision Sciences, Merck & Co., Inc., Rahway, NJ, USA

Kunal Saxenad Center for Observational and Real-World Evidence, Merck & Co., Inc., Rahway, NJ, USA

Athar Ali Tajikb MSD, Oslo, Norway

Wei Wanga Health Economic and Decision Sciences, Merck & Co., Inc., Rahway, NJ, USA

Cody Palmera Health Economic and Decision Sciences, Merck & Co., Inc., Rahway, NJ, USA

Your download is now in progress and you may close this window